In the News

As 2019 comes to an end, take a moment to reflect on the science stories that made the year one to remember.

Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team, have discovered that DNA circles can contribute to the development of childhood cancers. The team, led by MSK computational biologist Richard Koche and Anton Henssen of Charité University Hospital Berlin, made this discovery by studying extrachromosomal DNA in neuroblastoma cells. Neuroblastoma develops in immature nerve cells and is the most common form of cancer in infants.

Mysterious circular DNA may contribute to neuroblastoma and other childhood cancers.

About two dozen MSK physicians and researchers shared their work at the world’s leading breast cancer conference, held annually in San Antonio.

Memorial Sloan Kettering Cancer Center (MSK) today celebrates its 26th year of the "holiday hallway." Each year during December, MSK’s carpenters, toolmakers, locksmiths, electricians, and painters construct a winter wonderland in the basement hallway of MSK for patients, families, and staff to visit and enjoy. The decades-long tradition brings joy and cheer to all and has grown in size and detail year after year. The “holiday hallway” is a labor of love for MSK’s Facilities staff, who give of themselves to create the magical MSK tradition. 

As we approach the end of 2019, learn about some of the biggest advances in clinical research made this year at MSK.

MSK medical oncologist Shanu Modi is the lead author of a new paper detailing the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. Results from this study were also presented at the San Antonio Breast Cancer Symposium.

The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center will be home to the largest gathering of hematologic experts ever at Memorial Sloan Kettering Cancer Center (MSK), including specialists in blood and marrow stem cell transplants, chimeric antigen receptor T cell therapy, lymphoma, leukemia, multiple myeloma, and nonmalignant blood disorders.

The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center sets a new benchmark for sustainability and resiliency in a healthcare facility.

Two studies on multiple myeloma provide new information about diagnosing and treating this blood cancer.